top of page

Episcreen Liver goes beyond Screening and Surveillance

Our goal was to create one solution that caters to all aspects of liver cancer. Screening and surveillance was the first step. We have now discovered that the capabilities of the test goes beyond screening and surveillance and into the realms of treatment response and recurrence monitoring.

When integrated with machine learning, early data from 100+ HCC patients suggest a possibility of staging the cancer...just from the drop of blood using Episcreen Liver

Treatment response marker

Treatment response markers play a crucial role in assessing the effectiveness of various therapies. These markers help clinicians monitor how well a patient is responding to treatment and make informed decisions regarding the continuation or change of therapy. 

World's FIRST Epigenetic-based treatment response marker

Episcreen Liver has been tested in a pilot study and is proven to be an effective treatment response marker


Works for all interventions

Locoregional therapies such as TACE, TARE, MWA and SBRT

Surgical Resection and Liver Transplant

Pilot clinical study: Hypermethylation patterns changed from "Signal Detected" to "Signal not detected" for 90% of the patients within 4 weeks.

The application of Episcreen Liver goes beyond screening and surveillance and can be used as a tool for monitoring treatment efficacy and as tool for monitoring down-staging of HCC.

Multicentre study for use of Episcreen Liver as a treatment response marker is now initiated. 

Recurrence Monitoring

Recurrence monitoring is a critical aspect of managing HCC patients, as HCC has a relatively high risk of recurrence even after successful treatment. The recurrence monitoring process involves regular follow-up and surveillance to detect any signs of tumor recurrence

Recurrence Monitoring.jpg
Abstract Sphere

Potential for Cancer Staging

Episcreen Liver clinical study suggested good correlation between the stage of cancer and methylation levels when integrated with Machine Learning.  Well defined clustering based on the cancer stage and Episcreen Liver derived methylation levels was observed in the study with 82.5% of the subjects falling in respective BCLC staging.


This indicates a notable advancement in the prospect of predicting and sub-stratification of the cancer stage through methylation profiling to enhance strategies for HCC management.

Imagine exploration beyond the current boundaries 

Companion Diagnostic for existing solutions

Discovery Assistant for innovative interventions

Important Safety Information


The Episcreen Liver screening test is recommended for use in adults with an elevated risk for Liver cancer, such as chronic liver disease patients. The Episcreen Liver test detects only Hepatocellular carcinoma and does not detect all liver cancers. This test should be used in addition to routine screening and surveillance liver cancer tests recommended by a healthcare provider. Episcreen Liver test is intended to detect HCC signals to corroborate the possible presence of the carcinoma. Use of Episcreen Liver test is recommended in individuals who are 18 years and older. The test performance decreases above the age of 75.


Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Methylation Signal Detected or Low Risk” does not rule out HCC. A test result of “Methylation Signal Detected or High Risk” requires confirmatory diagnostic evaluation by medically established procedures (e.g. radiological imaging) to confirm cancer. In some cases (about 2%), the hypermethylation patterns exists in-between the 2 levels and is deemed “Indeterminate or Intermediate” necessitating closer follow-up.


The results, although qualitatively represented, also is quantitative and can be used as personalized methylation patterns.If HCC is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the presence of some other cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory and Test Information

This screening test is purely done for information purposes only. Tvaster Genkalp Pvt. Ltd. will not be accountable for any treatment or medication prescribed as a result of the test outcome. Although this test is highly accurate, there is still a possibility of false positive (~ 10%) and false negative (~ 10%) results. This is due to the technical limitations and/or the biological limitations, including but not limited to low cfDNA in the patient blood, interference from genomic DNA from lysed blood cells causing increased background noise or other rare molecular events. Patient samples with insufficient cfDNA cannot be analyzed. In which case, the patient can choose to give the blood sample again for re-extraction of cfDNA that might or might not lead to additional charges. Or else, the patient can choose to not have the test done. Tvaster Genkalp Pvt. Ltd. will not be accountable for any consequences as a result of treatment regimen decisions of oncologists. The test results are not valid for medico-legal purposes. This test has not been approved by any regulatory bodies. This test is lab developed test (LDT) and validated under real world clinical scenario by Tvaster Genkalp Private Limited. The test performance pertains to the validation. The test is carried out by Tvaster Genkalp Pvt. Ltd. 

bottom of page